RxDoctor Payments Data

Julienne Kala, NP

Family · Hagerstown, MDNPI 1558911206

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 29.3% of the total. Reporting peaked in 2023 at $1,412 and has fallen 64.1% since, to $508 in 2025. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,316in general payments, 2019–2025

Across 357 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Collegium Pharmaceutical, Inc.$890
  • Mallinckrodt Hospital Products Inc.$475
  • Vertos Medical, Inc.$347
  • Boston Scientific$326
  • Medtronic$248
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$190%
  • Food & beverage$5,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,316 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland →

Medicare billing

Part B allowed, 2024
$274,532
Medicare patients
339
Services billed
2,658

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate238$156,975
OxycontinOxycodone Hcl98$72,062
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,009$27,963
RelistorMethylnaltrexone Bromide11$17,179
Fentanyl148$15,417
Oxycodone Hcl937$14,164
Morphine Sulfate ErMorphine Sulfate555$13,892
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen550$12,448
BelbucaBuprenorphine Hcl13$8,155
Buprenorphine34$7,994
Hydromorphone ErHydromorphone Hcl11$6,060
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$4,563
Gabapentin331$4,036
Pregabalin248$3,920
Methadone Hcl177$3,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$890$165,130251 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,556$17,17911 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone, Buprenorphine Hcl$14$14,965176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Hagerstown

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →